Review
Immunology
XiaoQin Lu, Rui Hu, Lin Peng, MengSi Liu, Zhen Sun
Summary: "Seven biosimilars of adalimumab approved for rheumatoid arthritis treatment by FDA and/or EMA have shown similar efficacy, safety, and immunogenicity to adalimumab, with switching trials indicating no significant impact on these factors."
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biotechnology & Applied Microbiology
Muhammad Safwan Akram, Neelam Pery, Lucy Butler, Muhammad Imtiaz Shafiq, Nayab Batool, Muhammad Fayyaz Ur Rehman, Luke G. Grahame-Dunn, Ali K. Yetisen
Summary: Global healthcare systems are facing challenges in funding innovative treatment costs, particularly in the biosimilars market as patent expirations approach for well-known monoclonal antibodies. The development costs of biosimilars are significantly higher than generic equivalents due to therapeutic trials and manufacturing expenses, impacting efforts to lower prices for cancer and autoimmune disorder treatments. Academic and industry understanding of the complex costs and stages of biologics processing is crucial for navigating the evolving landscape of healthcare.
CRITICAL REVIEWS IN BIOTECHNOLOGY
(2021)
Article
Rheumatology
Daniel E. Furst, Janusz Jaworski, Rafal Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec, Slawomir Jeka, Agnieszka Zielinska, Jakub Trefler, Katarzyna Bartnicka-Maslowska, Magdalena Krajewska-Wlodarczyk, Piotr A. Klimiuk, Sang Joon Lee, Sung Hyun Kim, Yun Ju Bae, Go Eun Yang, Jae Kyoung Yoo, Jonathan Kay, Edward Keystone
Summary: The study found that the efficacy, pharmacokinetics, safety, and immunogenicity of CT-P17 and reference adalimumab were comparable after one year of treatment, including after switching from reference adalimumab to CT-P17.
Article
Dermatology
Astrid M. van Huizen, Gayle E. van der Kraaij, Celine I. Busard, Wouter Ouwerkerk, Juul M. P. A. van den Reek, Stef P. Menting, Errol P. Prens, Theo Rispens, Annick de Vries, Elke M. G. J. de Jong, Jo Lambert, Martijn B. A. van Doorn, Phyllis I. Spuls
Summary: This study compared the long-term effectiveness and safety of the combination of methotrexate and adalimumab with adalimumab monotherapy in patients with moderate to severe plaque type psoriasis. The results showed a trend towards longer drug survival in the combination therapy group, but no significant difference was found compared to the monotherapy group. Similar conclusions were drawn regarding the efficacy, safety, pharmacokinetics, and immunogenicity of the drugs. Overall, combination therapy may have a better effect in individual patients.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Pharmacology & Pharmacy
Alexander Vugler, James O'Connell, Mai Anh Nguyen, Dietmar Weitz, Thomas Leeuw, Elizabeth Hickford, Alexander Verbitsky, Xiaoyou Ying, Markus Rehberg, Bruce Carrington, Mark Merriman, Andrew Moss, Jean-Marie Nicholas, Phil Stanley, Sara Wright, Tim Bourne, Yann Foricher, Daniel Brookings, Helen Horsley, Matthias Herrmann, Srinivas Rao, Markus Kohlmann, Peter Florian
Summary: This article reports the discovery and development of a potent small molecule inhibitor of TNF, SAR441566, which has shown potential as a treatment option for chronic autoimmune diseases. By stabilizing an asymmetrical form of TNF and compromising its functions, SAR441566 offers a promising alternative to established biologic drugs targeting TNF.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Emilia Anderson, Karen Waller, Aravind Gokul Tamilarasan, Huiyu Lin, Sudarshan Paramsothy, Rupert W. Leong
Summary: This article compares and contrasts originator and biosimilar adalimumab agents, identifying key differences such as product formulation, dosages available, delivery devices, physician support, patient support, and the supply of other biosimilar products by the company. Therefore, the choice of agent should be individualized to the needs of the patient and the healthcare service.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Article
Medicine, General & Internal
Guillaume Larid, Guy Baudens, Alexis Dandurand, Pascal Coquerelle, Vincent Goeb, Marie Helene Guyot, Laurent Marguerie, Frederic Maury, Eric Veillard, Eric Houvenagel, Jean-Hugues Salmon, Rene-Marc Flipo, Elisabeth Gervais
Summary: This study compared the treatment retention of subcutaneous boDMARDs and bsDMARDs in different diseases, molecules, and lines of treatment. The results showed that bsDMARDs had significantly better retention than boDMARDs, especially for ETN and patients with RA. Citrated treatments demonstrated better retention.
FRONTIERS IN MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Ammar Almaaytah
Summary: The development of monoclonal antibodies has revolutionized the pharmaceutical industry by providing clinicians with a wide range of therapeutic options. Unlike small molecule drugs, monoclonal antibodies are large and complex molecules produced through genetic engineering. With several originator biological agents losing their patents, pharmaceutical manufacturers are now pursuing the development of generic biopharmaceuticals or "biosimilars" as alternative therapeutics.
Article
Pediatrics
Lili Ye, Yingying Jin, Hua Huang, Fei Ding, Xuemei Xu, Chenxi Liu, Shengfang Bao, Jing Wu, Yanliang Jin
Summary: This study explored the role of DKK-1 and SOST in the pathogenesis of JIA. It was found that plasma levels of DKK-1 were significantly higher in JIA patients, especially in those with HLA-B27 positivity. After treatment, DKK-1 levels decreased significantly. However, there was no significant change in SOST levels among different JIA subtypes, before and after treatment, and healthy controls.
PEDIATRIC RESEARCH
(2023)
Article
Immunology
Jing-Wen Chen, Guo-Shu Deng, Wen-Shuang Zhang, Ming-Ying Zhang, Tong Guan, Qiang Xu
Summary: This study reported the first successful case of a 60-year-old HIV-positive woman with difficult-to-treat RA who was treated with ADA therapy. It was found that adalimumab is a safe option for patients with RA-HIV and may slow down the progression of HIV infection. Furthermore, HAART therapy has the potential to reduce joint pain and fatigue in patients with difficult-to-treat RA.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Dermatology
Tasnim Abdalla, Mark Mansour, Dorra Bouazzi, Michelle A. Lowes, Gregor B. E. Jemec, Afsaneh Alavi
Summary: This study examined serum adalimumab concentrations and anti-adalimumab antibody status in 38 patients with moderate-to-severe hidradenitis suppurativa who had suboptimal response to adalimumab therapy. The results showed that patients with anti-adalimumab antibodies had significantly lower adalimumab levels, suggesting that therapeutic drug monitoring may help identify reasons for suboptimal response and guide dose optimization strategies.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2021)
Review
Pharmacology & Pharmacy
Zvonimir Petric, Joao Goncalves, Paulo Paixao
Summary: Monoclonal antibodies have revolutionized the treatment of chronic inflammatory diseases, but they face challenges related to their immunogenicity, effectiveness, and safety. Biosimilars have emerged as a cost-effective alternative and have been shown to be as safe and effective as the originator drugs in treating IBD patients.
Article
Oncology
Feicheng Wang, Nathan Palmer, Kathe Fox, Katherine P. P. Liao, Kun-Hsing Yu, Samuel C. C. Kou
Summary: Rheumatoid arthritis is associated with increased risks of developing various types of cancer, including lymphoma and lung cancer. However, the study found that the treatments commonly used for rheumatoid arthritis are not significantly linked to an increased cancer risk. This suggests that the pathophysiology of rheumatoid arthritis itself, rather than its treatments, plays a key role in the development of subsequent cancers.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Review
Multidisciplinary Sciences
Thomas M. Herndon, Cristina Ausin, Nina N. Brahme, Sarah J. Schrieber, Michelle Luo, Frances C. Andrada, Carol Kim, Wanjie Sun, Lingjie Zhou, Stella Grosser, Sarah Yim, M. Stacey Ricci
Summary: This study found no differences in safety profiles or immunogenicity rates between patients who were switched between reference biologics and biosimilars and those who remained on either a reference biologic or a biosimilar.
Article
Immunology
Jose Manuel Sanchez-Maldonado, Rafael Caliz, Miguel Angel Lopez-Nevot, Antonio Jose Cabrera-Serrano, Ana Moniz-Diez, Helena Canhao, Rob Ter Horst, Luca Quartuccio, Signe B. Sorensen, Bente Glintborg, Merete L. Hetland, Ileana Filipescu, Eva Perez-Pampin, Pablo Conesa-Zamora, Jerzy Swierkot, Alfons A. den Broeder, Salvatore De Vita, Eva Rabing Brix Petersen, Yang Li, Miguel A. Ferrer, Alejandro Escudero, Mihai G. Netea, Marieke J. H. Coenen, Vibeke Andersen, Joao E. Fonseca, Manuel Jurado, Katarzyna Bogunia-Kubik, Eduardo Collantes, Juan Sainz
Summary: This study confirmed the influence of the LINC02549 and LRRC55 loci on determining the response to TNFi in RA patients, while suggesting a weak effect of the MAFB and CNTN5 loci that require further investigation.
FRONTIERS IN IMMUNOLOGY
(2021)